ERBB2 and cancer: This molecular classification has significant clinical implications: Luminal A cancers, which are often low-grade and slow-growing, have the greatest prognosis, whereas Triple-negative and some HER2-enriched tumors exhibit more aggressive evolution and a poorer prognosis in the absence of targeted therapy [25].